Vanda Pharmaceuticals, Inc. (VNDA)
3.75
+0.16
(+4.46%)
USD |
NASDAQ |
Nov 06, 10:36
Vanda Pharmaceuticals Total Liabilities (Quarterly) : 182.47M for Sept. 30, 2026
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 182.47M |
| June 30, 2026 | 192.28M |
| March 31, 2026 | 152.76M |
| December 31, 2025 | 161.76M |
| September 30, 2025 | 135.14M |
| June 30, 2025 | 138.42M |
| March 31, 2025 | 120.52M |
| December 31, 2024 | 117.66M |
| September 30, 2024 | 103.89M |
| June 30, 2024 | 108.86M |
| March 31, 2024 | 108.69M |
| December 31, 2023 | 103.53M |
| September 30, 2023 | 98.50M |
| June 30, 2023 | 101.78M |
| March 31, 2023 | 108.79M |
| December 31, 2022 | 107.05M |
| September 30, 2022 | 106.13M |
| June 30, 2022 | 100.55M |
| March 31, 2022 | 101.44M |
| December 31, 2021 | 88.86M |
| September 30, 2021 | 86.45M |
| June 30, 2021 | 86.42M |
| March 31, 2021 | 75.56M |
| December 31, 2020 | 80.19M |
| September 30, 2020 | 75.33M |
| Date | Value |
|---|---|
| June 30, 2020 | 75.05M |
| March 31, 2020 | 72.14M |
| December 31, 2019 | 72.80M |
| September 30, 2019 | 73.54M |
| June 30, 2019 | 75.79M |
| March 31, 2019 | 72.76M |
| December 31, 2018 | 56.71M |
| September 30, 2018 | 50.52M |
| June 30, 2018 | 51.66M |
| March 31, 2018 | 76.17M |
| December 31, 2017 | 74.04M |
| September 30, 2017 | 75.24M |
| June 30, 2017 | 79.25M |
| March 31, 2017 | 76.58M |
| December 31, 2016 | 79.04M |
| September 30, 2016 | 79.28M |
| June 30, 2016 | 80.42M |
| March 31, 2016 | 83.73M |
| December 31, 2015 | 80.02M |
| September 30, 2015 | 74.61M |
| June 30, 2015 | 73.95M |
| March 31, 2015 | 61.17M |
| December 31, 2014 | 10.89M |
| September 30, 2014 | 78.11M |
| June 30, 2014 | 85.29M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| SELLAS Life Sciences Group, Inc. | 7.726M |
| Protagonist Therapeutics, Inc. | 44.00M |
| Sagimet Biosciences, Inc. | 7.275M |
| ACADIA Pharmaceuticals, Inc. | 406.66M |
| Alnylam Pharmaceuticals, Inc. | 4.391B |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 382.33M |
| Shareholders Equity (Quarterly) | 199.86M |
| Debt to Equity Ratio | 0.1099 |
| Current Ratio | 1.539 |
| Net Debt Paydown Yield | -0.70% |